VitriVax Inc.
The University of Colorado Connection
VitriVax is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics based on research in the laboratories of (¶¶ÒõÂÃÐÐÉä Boulder Molecular, Cellular & Developmental Biology) and Ìýat ¶¶ÒõÂÃÐÐÉä Boulder (¶¶ÒõÂÃÐÐÉä Boulder Chemical and Biological Engineering).
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech​, Manufacturing​, Therapeutics, Vaccines
- Funding Stage: Series B Round or beyond
- Contact for Investment Inquiries: Rom Colindres, CEO, rcolindres@vitrivaxbio.com
In the News
- New single-dose, temperature-stable rabies vaccines could expand global access (2025)
- (2024)
- VitriVax, a ¶¶ÒõÂÃÐÐÉä Boulder spinout, receives $5M grant from Gates Foundation (2023)
- VitriVax wins $29M Department of Defense contract for vaccine research (2023)
- New Buff Venture Fund makes landmark investments in ¶¶ÒõÂÃÐÐÉä Boulder startups (2023)
- Why developing a successful COVID-19 vaccine is only half the battle (2020)
- ¶¶ÒõÂÃÐÐÉä Boulder brings together top spinoffs from Colorado research institutions for Destination Startup (2019)
- State accelerator program fosters ¶¶ÒõÂÃÐÐÉä Boulder spin-off companies (2017)
Venture Partners Programs​
- Buff Gold Venture Fund (2023)
- Destination Startup (2019)
- Intellectual Property Management (2006)
Technology Development Funding
Gates Foundation
ÌýÌý ÌýThis page was last updated on April 14, 2025. Please email vpnews@colorado.edu for corrections or updates
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at ¶¶ÒõÂÃÐÐÉä Boulder.
For media inquiries, please visit .